Accordingly, tumour growth upon re‐challenge of long‐term survivors following neoadjuvant ILP‐TNF/Mel/SM was significantly delayed in comparison to survivors of the ILP‐TNF/Mel treatment arm (Fig 6E), indicating the induction of a degree of systemic anti‐tumour immunity. The gene discussed is TNF; the disease is neoplasm.